Why the study?
Procedural efficacy, safety, and 1-year freedom from AF recurrence had not been directly compared between the novel PolarX cryoballoon system and Arctic Front Advance Pro in patients with paroxysmal AF undergoing PVI.
Does the PolarX cryoballoon system improve 1-year freedom from AF recurrence compared to the Arctic Front Advance Pro in patients with paroxysmal atrial fibrillation?
Does the PolarX cryoballoon system improve 1-year freedom from AF recurrence compared to the Arctic Front Advance Pro in patients with paroxysmal atrial fibrillation?
The novel PolarX cryoballoon system demonstrates comparable 1-year efficacy for AF recurrence but a higher rate of transient phrenic nerve palsy compared to the established Arctic Front Advance Pro system.
Answers are grounded in this paper and cite their sources.
Similar recurrence rates with PolarX and AFA-Pro should not change practice; leaves open equivalence pending randomized trials.
AIMS: The aim of this study was to compare procedural efficacy and safety, including 1-year freedom from AF recurrence, between the novel cryoballoon system PolarX (Boston Scientific) and the Arctic Front Advance Pro (AFA-Pro) (Medtronic), in patients with paroxysmal AF undergoing PVI. METHODS AND RESULTS: This multicentre prospective observational study included 267 consecutive patients undergoing a first cryoablation procedure for paroxysmal AF (137 PolarX, 130 AFA-Pro). Kaplan-Meier curves with the log-rank test was used to compare the 1-year freedom from AF recurrence between both groups. Multivariate Cox model was performed to evaluate whether the type of procedure (PolarX vs. AFA-Pro) had an impact on the occurrence of AF recurrences after adjustment on potentially confounding factors. The PolarX reaches lower temperatures than the AFA-Pro (LSPV 52 ± 5, vs. 59 ± 6; LIPV 49 ± 6 vs. 56 ± 6; right superior pulmonary vein: 49 ± 6 vs. 57 ± 7; right inferior pulmonary vein: 52 ± 6 vs. 59 ± 6; P < 0.0001). A higher rate of transient phrenic nerve palsy was found in patients treated with the PolarX system (15% vs. 7%, P = 0.05). After a mean follow-up of 15 ± 5 months, 20 patients (15%) had recurrences in AFA-Pro group and 27 patients (19%) in PolarX group (P = 0.35). Based on survival analysis, no significant difference was observed between both groups with a 12-month free of recurrence survival of 91.2% (85.1-95.4%) vs. 83.7% (76.0%-89.1%) (log-rank test P = 0.11). In multivariate Cox model hazard ratio of recurrence for PolarX vs. AFA-Pro was not significant [HR = 1.6 (0.9-2.8), P = 0.12]. CONCLUSION: PolarX and AFA-Pro have comparable efficacy and safety profiles for pulmonary veins isolation in paroxysmal atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Tanese et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: